


We're tackling cancer head-on.

At Mirati, we convert possibility into reality by developing **best-in-class targeted therapies** to improve the lives of patients.

[Our Programs](#)


Display a menu



KRAS

Our scientists are rigorously advancing research and development programs targeting the KRAS G12C and KRAS G12D mutations.

[> Explore our KRAS programs](#)



Sitravatinib

We are exploring new ways of targeting the protective nest of cells, tissues and blood vessels that make up the tumor microenvironment.

[> Explore our sitravatinib program](#)

Mirati is developing a pipeline
of novel therapeutics.

[Explore the Pipeline](#)





Become part of
something **bigger.**

Explore Careers at Mirati

Press Releases



05/06/2021

Mirati Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Updates >



04/19/2021

Stand Up to Cancer Announces \$4 Million Grant From Mirati Therapeutics to Support Research on KRAS Mutant Cancers >



04/10/2021

Mirati Therapeutics Presents Preclinical Data on Novel Approach to PRMT5 Inhibition that Selectively Targets the PRMT5/MTA Complex in MTAP-Deleted Cancer Models >



03/31/2021

Mirati Therapeutics Board Elects Shalini Sharp as New Independent Director >

[View all press releases](#)

MIRATI
THERAPEUTICS

© Copyright 2021 - Mirati Therapeutics, Inc.
858.332.3410 | info@mirati.com



[Terms of Use](#) | [Privacy Policy](#) | [Cookies Policy](#) | [Expanded Access Policy](#)

Display a menu